Point at sector perform by RBC

RBC Capital Markets analyst David Bouchey rated Point Therapeutics, Inc. at sector perform, speculative risk on encouraging updated clinical data for Talabostat in colorectal cancer, melanoma and chronic lymphocytic leukemia. Shares of the Boston-based biopharmaceutical company were down $0.09, or 3.21%, at $2.71 on volume of 114,938 shares versus the three-month running average of 86,892 shares. (Nasdaq: POTP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.